NR3C2 and metabolic syndrome: Furthermore, increased plasma aldosterone levels (Aroor et al. 2019, Vecchiola et al. 2020) and enhanced MR activation (DeMarco et al. 2015, Jia et al. 2016, Hulse et al. 2022) not only induce CVD but also contribute to glucose intolerance, dyslipidemia, and metabolic syndrome.